Live Breaking News & Updates on First Interventional Phase

WATERTOWN, Mass., March 13, 2024 Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases,. ....

United States , Davids Lynch , Megan Mcgrath , Zbigniew Wszolek , Leah Gibson , Abbie Renoux , Vigil Neuroscience Inc , Investor Relations Corporate Communications , University College London Institute Of Neurology , American Academy Of Neurology , National Hospital For Neurology Neurosurgery , Annual Meeting , Interim Results , First Interventional Phase , Adult Onset Leukoencephalopathy , Axonal Spheroids , Pigmented Glia , Mayo Clinic , Findings From , Natural History Study , National Hospital , University College London Institute , Enhances Microglial Survival , Investor Relations ,